Patient


  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the breakthrough cancer therapy that just won a historic FDA nod

    The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

    By Kelly Bilodeau • Feb. 21, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • digital pill Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Artificial intelligence & machine learning

    After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

    By PharmaVoice staff
  • pill loading
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    ‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

    Researchers are unleashing the powers of AI for precision medicine, drug development and more.

    By Alexandra Pecci • Feb. 15, 2024
  • Niesha Foster, Pfizer
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    ‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity

    The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.

    By Feb. 14, 2024
  • Drug pill question
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    These 4 drugs had tons of promise — and they flopped. What happened?

    No amount of excitement can prevent failures stemming from safety, efficacy, cost and other speed bumps along the way.

    By Alexandra Pecci • Feb. 13, 2024
  • neck pain stock
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Tonix closes in on the first new fibromyalgia drug in more than a decade

    In addition to the chronic disease, the non-opioid drug may have applications in other painful conditions.

    By Kelly Bilodeau • Jan. 29, 2024
  • Amylyx CEOs
    Image attribution tooltip
    Permission granted by Amylyx
    Image attribution tooltip
    Q&A

    ‘1 plus 1 equals 3’ — the co-CEO model in pharma

    Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

    By Jan. 26, 2024
  • 2024 outlook
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The biggest questions hanging over pharma in 2024

    Key trends on the horizon in the life sciences this year.

    By Jan. 25, 2024
  • King Charles III
    Image attribution tooltip
    Dan Kitwood/Getty Images via Getty Images
    Image attribution tooltip

    King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way

    The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.

    By Jan. 25, 2024
  • MRI machine
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Breast cancer tops list of most studied diseases

    The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.

    By Kelly Bilodeau • Jan. 24, 2024
  • hand syringe
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Controversial challenge trials offer unparalleled innovation — with ethical bumps

    Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.

    By Kelly Bilodeau • Jan. 22, 2024
  • Chris Arendt
    Image attribution tooltip
    Permission granted by Takeda Pharmaceuticals
    Image attribution tooltip

    Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention

    Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.

    By Jan. 19, 2024
  • Covid doctor
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    An enduring COVID mystery: Why some do fine and others die

    The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.

    By Alexandra Pecci • Jan. 17, 2024
  • gut microbiome
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma takes a gut check of microbiome drugs

    On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.

    By Kelly Bilodeau • Jan. 16, 2024
  • San Francisco
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    Pharma execs sound off on trends and policies they’re tracking in 2024

    From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.

    By Jan. 12, 2024
  • 2024 Crystal Ball Trials
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion // Year in Preview

    PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials

    As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.

    By Jan. 11, 2024
  • Black patient mental health
    Image attribution tooltip
    E+ via Getty Images
    Image attribution tooltip

    How J&J is tackling a ‘secondary pandemic’ in the Black community

    J&J is leading a grassroots effort to improve mental health access and care.

    By Alexandra Pecci • Jan. 8, 2024
  • DNA vile
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Regulatory twists and turns are coming for biopharma in 2024

    New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.

    By Kelly Bilodeau • Jan. 8, 2024
  • Alzheimer's patient
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Alzheimer’s research is hot, but successful patient recruitment will determine its future

    Key strategies for bringing more patients into the clinical trial fold.

    By Kelly Bilodeau • Jan. 4, 2024
  • pill explosion
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    10 of our most read articles in 2023

    A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.

    By Dec. 22, 2023
  • A gloved hand holds a DNA microscope slide.
    Image attribution tooltip

    Massachusetts General Hospital

    Image attribution tooltip
    Deep Dive

    As ALS research booms, one treatment center finds itself in the spotlight

    The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.

    By Jacob Bell • Dec. 22, 2023
  • blockbuster drugs
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    What are pharma’s next blockbusters?

    In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.

    By Kelly Bilodeau • Dec. 20, 2023
  • dollar sign
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 noteworthy pharma AI investments in 2023

    The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.

    By Alexandra Pecci • Dec. 19, 2023
  • Babson testing device
    Image attribution tooltip
    Permission granted by Babson Diagnostics
    Image attribution tooltip

    Babson gets one step closer to delivering on Theranos-like blood testing

    A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.

    By Kelly Bilodeau • Dec. 18, 2023
  • drug prices
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Study suggests PBMs are gaming pharmacy system to overcharge for drugs

    Markups for generics can be as high as 7,000%, the researchers said.

    By Alexandra Pecci • Dec. 15, 2023